7-benzyloxy-2-ethylchromane-2-carboxylic acid | 444341-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-benzyloxy-2-ethylchromane-2-carboxylic acid
• 英文别名: 2-ethyl-7-phenylmethoxy-3,4-dihydrochromene-2-carboxylic acid
• CAS: 444341-88-2
• 化学式: C₁₉H₂₀O₄
• 分子量: 312.365
• InChiKey: GSGBGLWXKAXCSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-benzyloxy-2-ethylchromane-2-carboxylic acid 在 4-二甲氨基吡啶 、 sodium hydroxide 、 氢气 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 20.0~65.0 ℃ 、344.74 kPa 条件下， 反应 5.0h， 生成 (S)-7-{3-[2-Chloro-4-(4-fluoro-phenoxy)-phenoxy]-propoxy}-2-ethyl-chroman-2-carboxylic acid methyl ester
  参考文献：
  名称：

  (2R)-2-Ethylchromane-2-carboxylic Acids:  Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents

  摘要：

  A series of chromane-2-carboxylic acid derivatives was synthesized and evaluated for PPAR agonist activities. A structure-activity relationship was developed toward PPARalpha/gamma dual agonism. As a result, (2R)-7-{3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy}-2-ethylchromane-2-carboxylic acid (48) was identified as a potent, structurally novel, selective PPARalpha/gamma dual agonist. Compound 48 exhibited substantial antihyperglycemic and hypolipidemic activities when orally administered in three different animal models: the db/db mouse type 2 diabetes model, a Syrian hamster lipid model, and a dog lipid model.

  DOI：

  10.1021/jm030621d
• 作为产物：
  描述：

  ethyl 7-hydroxychromane-2-carboxylate 在 六甲基磷酰三胺 、 sodium hydroxide 、 sodium hexamethyldisilazane 、 potassium carbonate 作用下， 以 四氢呋喃 、 异丙醇 、 丙酮 为溶剂， 反应 61.0h， 生成 7-benzyloxy-2-ethylchromane-2-carboxylic acid
  参考文献：
  名称：

  (2R)-2-Ethylchromane-2-carboxylic Acids:  Discovery of Novel PPARα/γ Dual Agonists as Antihyperglycemic and Hypolipidemic Agents

  摘要：

  A series of chromane-2-carboxylic acid derivatives was synthesized and evaluated for PPAR agonist activities. A structure-activity relationship was developed toward PPARalpha/gamma dual agonism. As a result, (2R)-7-{3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy}-2-ethylchromane-2-carboxylic acid (48) was identified as a potent, structurally novel, selective PPARalpha/gamma dual agonist. Compound 48 exhibited substantial antihyperglycemic and hypolipidemic activities when orally administered in three different animal models: the db/db mouse type 2 diabetes model, a Syrian hamster lipid model, and a dog lipid model.

  DOI：

  10.1021/jm030621d

文献信息

• Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
  申请人：——

  公开号：US20020082292A1

  公开（公告）日：2002-06-27

  A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

  苯并吡喃羧酸衍生物类别包括强效PPARα和/或γ激动剂化合物，因此在治疗、控制或预防非胰岛素依赖型糖尿病（NIDDM）、高血糖、血脂异常、高血脂症、高胆固醇血症、高甘油三酯血症、动脉粥样硬化、肥胖、血管再狭窄、炎症和其他PPARα和/或γ介导的疾病、紊乱和状况中具有用处。
• BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS
  申请人：Merck & Co., Inc.

  公开号：EP1324995A2

  公开（公告）日：2003-07-09
• US6645997B2
  申请人：——

  公开号：US6645997B2

  公开（公告）日：2003-11-11
• US6713508B2
  申请人：——

  公开号：US6713508B2

  公开（公告）日：2004-03-30
• [EN] BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS<br/>[FR] DERIVES D'ACIDE BENZOPYRANCARBOXYLIQUE UTILISES POUR LE TRAITEMENT DU DIABETE ET DES TROUBLES LIPIDIQUES
  申请人：MERCK & CO INC

  公开号：WO2002026729A2

  公开（公告）日：2002-04-04

  A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.